Accordingly, depletion of TAMs with anti-CSF1/CSF1R (CSF1 receptor) antibodies enhanced chemosensitivity to a combinatorial chemotherapeutic approach in human breast cancer xenografts (193) and a genetic mammary tumor model (194). This evidence concerns the gene CSF1 and breast cancer.